Allergan, Inc.
http://www.allergan.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Allergan, Inc.
Why Investing In ESG Measures Is Good For Medtech’s Health And Sustainability
For medtechs, implementing an ESG strategy will need to become a priority as global rules are being introduced for companies to report ESG data. A panel discussion with medtech ESG leaders at the recent LSX Congress USA conference in Boston outlined some strategies and sustainability goals.
J&J And Sanofi Team Up On Phase III E. Coli Vaccine
Sanofi will pay $175m up front for rights to commercialize J&J’s potential first-in-class vaccine against E. coli. The two companies will share profits.
Exkivity Withdrawal Is Blow To Takeda’s Oncology Ambitions
The withdrawal of the targeted anticancer comes as no surprise after its Phase III missed in July, but it sets back Takeda’s expansion plans in the competitive therapy area.
Next-Gen ADCs: Araris CEO Highlights Potential In Linker Technology
In Vivo sat down with 2023 Rising Leader Philipp Spycher, CEO of Araris Biotech, to discuss trends in antibody-drug conjugate R&D, and how Araris hopes to disrupt today’s chemotherapy treatment paradigm with novel linker technology.
Company Information
- Industry
-
Pharmaceuticals
- OTC, Consumer
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Site Specific
-
Medical Devices
- Implantable Devices
- Surgical Equipment & Devices
- Other Names / Subsidiaries
-
- Inamed
- MAP Pharmaceuticals, Inc. (MAPP)
- Oculex Pharmaceuticals, Inc.
- SkinMedica, Inc.
- Vicept
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice